1.
Cell Stem Cell
; 11(6): 735-9, 2012 Dec 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23217418
RESUMO
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.